Home › Hypopharyngeal Cancer
Hypopharyngeal Cancer clinical trials recruiting in the U.S.
19 studies for Hypopharyngeal Cancer are recruiting participants at sites across the United States.
Cities with the most studies
- Atlanta, GA6 studies
- Chicago, IL6 studies
- Joliet, IL5 studies
- Richmond, VA5 studies
- Wausau, WI5 studies
- Peoria, IL5 studies
- Cape Girardeau, MO5 studies
- Milwaukee, WI5 studies
- Stevens Point, WI5 studies
- Bloomington, IL5 studies
- Kansas City, MO5 studies
- Edison, NJ4 studies
- Queens, NY4 studies
- New York City, NY4 studies
- Danville, IL4 studies
- Lansing, MI4 studies
- Fargo, ND4 studies
- St. Louis, MO4 studies
- Omaha, NE4 studies
- Bozeman, MT4 studies
- Decatur, IL4 studies
- Evanston, IL4 studies
- North Peoria, IL4 studies
- Charleston, IL4 studies
- Green Bay, WI4 studies
- Flint, MI4 studies
- Cicero, IL4 studies
- Oklahoma City, OK4 studies
- Galesburg, IL4 studies
- Champaign, IL4 studies
- Cedar Rapids, IA4 studies
- Waukegan, IL4 studies
- Aurora, IL4 studies
- Duluth, MN4 studies
- Waterford, MI4 studies
- Naperville, IL4 studies
- Pittsburgh, PA4 studies
- Cincinnati, OH4 studies
- Baltimore, MD4 studies
- Louisville, KY4 studies
By state
- Arizona3 studies
- Arkansas4 studies
- California7 studies
- Colorado6 studies
- Florida8 studies
- Georgia6 studies
- Idaho3 studies
- Illinois7 studies
- Indiana4 studies
- Iowa6 studies
- Kansas6 studies
- Kentucky4 studies
- Maryland5 studies
- Massachusetts5 studies
- Michigan5 studies
- Minnesota6 studies
- Missouri6 studies
- Montana4 studies
- Nebraska4 studies
- New Jersey4 studies
- New York8 studies
- North Carolina5 studies
- North Dakota4 studies
- Ohio8 studies
- Oklahoma4 studies
- Oregon3 studies
- Pennsylvania6 studies
- South Dakota3 studies
- Texas3 studies
- Virginia5 studies
- Wisconsin6 studies
Recently updated studies
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT06589804Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Head and Neck Cancer in a Rural Midwest United States Population
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT06997068BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT05136196Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT05172245Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT02734537Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 3, 2026 · NCT07156227Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT06532279Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT07441681Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 29, 2026 · NCT04198766Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation
Recruiting
Ages 18 and older · All sexes · Updated Jul 16, 2026 · NCT06662058Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients"
Recruiting
Ages 18 and older · All sexes · Updated Jul 15, 2026 · NCT01365169Integrated Cancer Repository for Cancer Research
RecruitingObservational studyHealthy volunteers welcome
Ages 19 to 110 · All sexes · Updated Jun 29, 2026 · NCT02012699Blood Tests and Questionnaires in Studying Adherence to Preventative Swallowing Exercises in Participants With Metastatic Head and Neck Cancer
RecruitingObservational study
Ages 18 and older · All sexes · Updated Apr 15, 2026 · NCT03010150TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Mar 4, 2026 · NCT06868433A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Feb 19, 2026 · NCT07063212Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Feb 11, 2026 · NCT06636734Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck
Recruiting
Ages 18 and older · All sexes · Updated Feb 10, 2026 · NCT01473784Comparing an Investigational Scan (F-18 NaF PET/CT) to Standard of Care Imaging (F-18 FDG PET/CT) for Evaluating Vascular Complications in Patients Receiving Radiation Therapy for Head and Neck Cancer
RecruitingEarly phase 1
Ages 18 and older · All sexes · Updated Oct 22, 2025 · NCT06914999Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers
RecruitingObservational study
Ages 21 to 90 · All sexes · Updated Sep 22, 2025 · NCT00900419From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.